Understanding the genetic and molecular heterogeneity of familial combined hyperlipidemia may provide insights into the pathophysiology of coronary artery disease.
Answers are grounded in this paper and cite their sources.
Does not yet change FCHL management; leaves open targeted genetic investigations into CAD pathways.
Familial combined hyperlipidemia (FCHL) is a dyslipidemic syndrome prevalent in patients with coronary artery disease. Other phenotypes that appear to have a kinship with FCHL include hyperapobetalipoproteinemia, LDL subclass pattern B, familial dyslipidemic hypertension, and syndrome X. The metabolic, genetic, and molecular basis of FCHL is heterogeneous. This review discusses the influence of eight putative loci as a basis for this heterogeneity. Further understanding of the fundamental defects underlying FCHL and related syndromes may provide important insights into the pathophysiology of coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Peter O. Kwiterovich (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: